Three APOE gene variants—ɛ2, ɛ3, and ɛ4—are investigated with regard to the risks of cardiovascular diseases and metabolic disorders, including dyslipidemia and insulin resistance [34,35,36]. This evidence concerns the gene APOE and metabolic disease.